Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine comment period extended to Sept. 27.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE COMMENT PERIOD EXTENDED UNTIL SEPT. 27, FDA announced in an Aug. 29 Federal Register notice. The agency is giving industry more time to respond to its July 27 notice of proposed rulemaking to amend the monograph for over-the-counter bronchodilator drug products. The amendment would ban ephedrine's use in over-the-counter drugs due to its role as a precursor in the manufacture of controlled substances such as methamphetamine and methcathinone ("The Tan Sheet" July 31, p. 1).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel